关于北京热景生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 关于北京热景生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况专项说明 容诚专字[2025]100Z0579号 目 录 1、 专项审计报告 2、 附表 委托单位：北京热景生物技术股份有限公司 审计单位：容诚会计师事务所（特殊普通合伙） 联系电话：010-66001391 本专项说明仅供热景生物公司年度报告披露之目的使用,不得用作任何其他 目的。 附件:北京热景生物技术股份有限公司 2024年度非经营性资金占用及其他关 联资金往来情况汇总表。 (此页无正文,为热景生物公司容诚专字[2025]100Z0579 号报告之签字盖章 页。) 中国注册会计师: 1003239 刘诚 洪伟 中国注册会计师: 刘洪伟 中国注册会计师: 中国·北京 张旭 北京热景生物技术股份有限公司全体股东: 我们接受委托,依据中国注册会计师审计准则审计了北京热景生物技术股份 有限公司(以下简称热景生物公司)2024年12月31日的合并及母公司资产负债 表,2024年度的合并及母公司利润表、合并及母公司现金流量表和合并及母公司 所有者权益 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-032 北京热景生物技术股份有限公司 2024 年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会证监发行字[2019]1615 号文核准，本公司于 2019 年 9 月向社会公开发行人民币普通股（A 股）1,555.00 万股，每股发行价为 29.46 元，应募集资金总额为人民币 45,810.30 万元，根据有关规定扣除发行费用 5,903.21 万元后，实际募集资金金额为 39,907.09 万元。该募集资金已于 2019 年 9 月到账。上述资金到账情况业经容诚会计师事务所（特殊普通合伙）会验字 [2019]7401 号《验资报告》验证。公司对募集资金采取了专户存储管理。 2024 年度，本公司募集资金使用情况为：（1）上述募集资金到账前，截至 2019 年 9 月 24 日止，公司利用自筹资金对募集资金项目累计已投入 531.40 万元， 募集资金到账后，公司以募集资 ...

北京热景生物技术股份有限公司 2024 年度"提质增效重回报"行动方案评估报告 暨 2025 年度"提质增效重回报"行动方案 为深入贯彻党的二十大和中央金融工作会议精神，认真落实国务院《关于进 一步提高上市公司质量的意见》的要求，积极响应上海证券交易所《关于开展沪 市公司"提质增效重回报"专项行动的倡议》，着力推动公司高质量发展，提升 公司投资价值，保护投资者尤其是中小投资者的合法权益，北京热景生物技术股 份有限公司（以下简称"公司"、"热景生物"）于 2024 年 4 月 30 日发布了公 司《2024 年度"提质增效重回报"行动方案》，2024 年 8 月 30 日发布了公司 《2024 年度"提质增效重回报"行动方案》的半年度评估报告。为切实维护投资 者利益，进一步提升公司质量和投资价值，公司对《2024 年度"提质增效重回 报"行动方案》进行了年度评估，并制定了《2025 年度"提质增效重回报"行 动方案》，此方案于 2025 年 4 月 28 日经公司第三届董事会第二十八次会议审议 通过。 一、聚焦经营主业，提升原研创新的核心驱动力 热景生物是一家以"发展生物科技，造福人类健康"为使命的生物高新技 ...

公司代码：688068 公司简称：热景生物 北京热景生物技术股份有限公司 2024年度内部控制评价报告 北京热景生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 2. 财务报告内部控制评价结论 √有效 □无效 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准日，不存在财务报告内 部控制重大缺陷，董事会认为，公司已按照企业内部控制规范体系和相关规定的要求在所有重大方面保 持了有效的财务报告内部控制。 3. 是否发现非财务报告内部控制重大缺陷 □是 √否 根据公司非财务报告内部控制重大缺陷认定情况，于内部控制评价报告基准日，公司未发现非财务 报告内部控制重大缺陷。 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-031 北京热景生物技术股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 22 日 14 点 30 分 召开地点：北京市大兴区中关村科技园区大兴生物医药产业基地庆丰西路 55 号公司三层会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 （七） 涉及公开征集股东投票权 无 二、 会议审议事项 本次股东大会审议议案及投票股 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-029 北京热景生物技术股份有限公司 第三届监事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京热景生物技术股份有限公司（以下简称"公司"）第三届监事会第二十 次会议于 2025 年 4 月 28 日以现场和通讯相结合的方式在公司三层会议室召开。 本次会议的通知于 2025 年 4 月 18 日以邮件等方式送达全体监事。本次会议应出 席监事 3 人，实际出席监事 3 人，会议由监事会主席许立达主持。会议的召集、 召开符合《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》等 相关法律、行政法规、规范性文件及《公司章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于<2024 年年度报告>全文及其摘要的议案》 公司 2024 年年度报告及摘要的编制和审核程序符合法律、法规及《公司章 程》等相关规定，内容真实、准确地反映了报告期内公司的经营情况和财务状况， 不存在任何虚假记载、误导性陈述或者重大 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-030 北京热景生物技术股份有限公司 第三届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京热景生物技术股份有限公司（以下简称"公司"）第三届董事会第二十 八次会议于 2025 年 4 月 28 日以现场和通讯相结合的方式在公司三层会议室召开。 本次会议的通知于 2025 年 4 月 18 日通过邮件等通讯方式送达至公司全体董事。 本次会议由董事长林长青先生主持，会议应到董事 7 人，实到董事 7 人，公司监 事及高级管理人员列席本次董事会会议。本次会议的召集和召开符合《中华人民 共和国公司法》《上海证券交易所科创板股票上市规则》等相关法律法规、规范 性文件及《北京热景生物技术股份有限公司章程》（以下简称"《公司章程》"）的 有关规定。 二、董事会会议审议情况 1、审议通过《关于<2024 年年度报告>全文及其摘要的议案》 具体内容详见公司同日于指定信息披露媒体披露的《北京热景生物技术股份 有限公司 2 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-024 北京热景生物技术股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京热景生物技术股份有限公司（以下简称"公司"）2024年归属于上 市公司股东净利润为负，根据相关法律法规以及《公司章程》等规定，2024年度 拟不进行利润分配，也不进行资本公积金转增股本和其他形式的分配。 公司2024年度利润分配预案已经公司第三届董事会第二十八次会议、第 三届监事会第二十次会议审议通过，尚需提交公司2024年年度股东大会审议。 公司不触及《上海证券交易所科创板股票上市规则》（以下简称"《科 创板股票上市规则》"）第12.9.1条第一款第（八）项规定的可能被实施其他风 险警示的情形。 一、2024年度利润分配方案内容 （一）利润分配方案的具体内容 经容诚会计师事务所(特殊普通合伙)审计，公司 2024 年度归属于上市公司 股东的净利润为-191,004,566.74 元。 经公司第三届董事会第二十八次会 ...

Financial Performance - The company's revenue for 2024 was CNY 510,900,037.23, a decrease of 6.74% compared to CNY 547,836,199.48 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY -191,004,566.74, representing a significant decline of 760.40% from CNY 28,922,432.95 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY -37,162,581.27, an improvement of 23.43% compared to CNY -48,531,914.50 in 2023[22]. - The total assets at the end of 2024 were CNY 3,325,861,626.00, down 6.88% from CNY 3,571,517,927.61 at the end of 2023[23]. - The basic earnings per share for 2024 was CNY -2.12, a decrease of 742.42% from CNY 0.33 in 2023[23]. - The gross profit margin for 2024 was 55.36%, a decrease of 1.77 percentage points compared to 2023[175]. - The company reported a net loss of CNY 150.37 million in Q4 2024, with a total revenue of CNY 124.74 million for the same quarter[29]. - The company achieved operating revenue of 510.90 million yuan, a year-on-year decrease of 6.74%[171]. - The net profit attributable to the parent company was CNY -191.00 million, a year-on-year decline of 760.40%[171]. Research and Development - The company invested a total of 113.31 million yuan in R&D for 2024, accounting for 22.18% of its revenue[51]. - The R&D expenditure as a percentage of revenue for 2024 was 22.18%, a decrease of 2.08 percentage points from 24.26% in 2023[23]. - The company has developed a proprietary GlyExo-Capture® platform for liquid biopsy, achieving significant breakthroughs in glycan chain abnormal protein capture and exosome detection technologies, with international and domestic patents obtained[140]. - The company has established the "X-Gen AI Drug Discovery and Design Research Center" to accelerate drug development using advanced AI technologies[50]. - The company has undertaken a total of 12 new and ongoing research projects, including 5 national key R&D projects under the "14th Five-Year Plan"[55]. - The company has published over 20 original research papers in top-tier journals like Nature and Cell, showcasing its leading position in the in vitro diagnostics industry[152]. - The company has developed a breakthrough liver-targeted delivery technology platform, which is expected to provide broader treatment strategies for liver-targeted diseases[151]. Market and Competitive Landscape - The company operates in a highly competitive in vitro diagnostic industry, where rapid technological advancements and product updates pose risks to maintaining market competitiveness[166]. - The in vitro diagnostic industry is experiencing intensified competition, with both domestic and international players vying for market share, which could negatively impact the company's market position and profitability[168]. - The global in vitro diagnostic (IVD) market is projected to reach $118 billion in 2024, with the non-COVID IVD market growing at a rate of 6.2%[86]. - The domestic IVD industry is undergoing structural changes, with the localization rate of upstream raw materials increasing to 35%[87]. - The company is focusing on innovative drug development, leveraging AI to enhance the efficiency of antibody and nucleic acid drug pipelines[81]. Corporate Governance and Compliance - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[9]. - The board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[3]. - The company has not achieved profitability since its listing[3]. - The company has committed to improving internal governance and control systems, ensuring timely and accurate information disclosure to investors[60]. Risks and Challenges - The company faces risks related to the failure of innovative drug development, particularly during clinical trials, which could significantly impact future growth and investment expectations[161]. - The pricing of diagnostic products is subject to government policies and market competition, which may lead to price declines if the company fails to innovate and introduce new products[165]. - The company must continuously upgrade its products to meet market demands; failure to do so could adversely affect future revenue growth and profitability[162]. - Future R&D investments are expected to increase further due to the acceleration of clinical projects in associated companies, which may lead to additional investment losses for the company[160]. Product Development and Innovations - The company has developed a liver cancer risk warning model (C-GALAD) that outperforms two major international models, aiding in early liver cancer diagnosis[41]. - The company has established a digital intelligent diagnosis model for liver disease risk warning, integrating clinical data with AI algorithms[67]. - The company has launched the "GlyExo-Capture® exosome rapid separation system" and the "EXO-01 exosome microRNA automatic detection instrument," marking significant advancements in exosome extraction automation[115]. - The company has received clinical trial approvals for the SGC001 project from both the FDA and the CDE, aimed at treating acute myocardial infarction patients[113]. - The company has developed a comprehensive STAT testing solution for emergency diagnostics, achieving a new breakthrough in chemiluminescence testing with a throughput of 600 tests per hour[42]. Financial Health and Investments - The company's total foreign assets amounted to 9,059,558.81 RMB, representing 0.27% of the total assets[200]. - The company's undistributed profits decreased to 2,737,758,221.52 RMB, reflecting a decline of 7.07% compared to the previous period[200]. - The company incurred an investment loss of CNY 43.61 million from its joint ventures, which increased R&D spending in innovative drug and early cancer screening fields[25]. - The company recognized impairment losses of CNY 83.12 million during the reporting period due to intensified competition in the industry[25].

Financial Performance - The company's operating revenue for Q1 2025 was ¥93,241,595.44, a decrease of 19.71% compared to ¥116,124,860.44 in the same period last year[4] - The net profit attributable to shareholders was -¥24,008,215.62, representing a decline of 574.96% from a profit of ¥5,054,819.80 in the previous year[4] - Net profit for Q1 2025 was a loss of ¥24,566,770.04, compared to a profit of ¥3,530,809.12 in Q1 2024, representing a significant decline[16] - The company reported a total comprehensive loss of ¥24,249,332.36 for Q1 2025, compared to a comprehensive income of ¥3,530,809.12 in Q1 2024[16] - Basic and diluted earnings per share were both -¥0.26, a decline of 533.33% from ¥0.06 in the same period last year[4] - Basic and diluted earnings per share for Q1 2025 were both -¥0.26, down from ¥0.06 in Q1 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities was -¥9,857,827.91, an improvement of 29.62% compared to -¥14,007,005.61 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was a net outflow of ¥9,857,827.91, an improvement from a net outflow of ¥14,007,005.61 in Q1 2024[17] - Cash and cash equivalents decreased to CNY 179,150,227.74 from CNY 270,149,505.21, representing a decline of approximately 33.73%[12] - Cash and cash equivalents at the end of Q1 2025 were ¥179,143,652.74, down from ¥234,606,511.59 at the end of Q1 2024[18] - Investment activities resulted in a net cash outflow of ¥60,210,905.55 in Q1 2025, compared to a net inflow of ¥63,265,564.93 in Q1 2024[18] - Financing activities led to a net cash outflow of ¥21,661,165.53 in Q1 2025, compared to a net outflow of ¥86,960,469.79 in Q1 2024[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,271,800,843.47, a decrease of 1.63% from ¥3,325,861,626.00 at the end of the previous year[5] - The company's current assets totaled CNY 1,469,794,285.16, an increase of 13.73% compared to CNY 1,292,423,310.23 at the end of 2024[13] - The company's total liabilities increased to CNY 289,666,459.87 from CNY 251,766,081.35, marking an increase of about 15.04%[14] - The total equity attributable to shareholders decreased to CNY 2,984,120,971.24 from CNY 3,075,526,738.85, a decline of approximately 2.97%[14] - The total non-current assets decreased to CNY 1,802,006,558.31 from CNY 2,033,438,315.77, reflecting a decline of approximately 11.37%[13] Operational Metrics - Research and development expenses totaled ¥20,426,393.23, accounting for 21.91% of operating revenue, an increase of 2.39 percentage points from 19.52%[5] - The decline in net profit was primarily due to a decrease in operating revenue and changes in product mix, leading to reduced gross profit[7] - The accounts receivable rose to CNY 113,821,794.92, up from CNY 91,877,262.84, indicating a growth of about 23.87%[12] - The company's inventory slightly decreased to CNY 80,360,959.86 from CNY 83,454,876.76, a reduction of approximately 3.36%[13] - The company reported a decrease in employee compensation payable to CNY 15,665,780.79 from CNY 20,364,491.39, a reduction of about 22.93%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,662[9]